Claim Missing Document
Check
Articles

Found 2 Documents
Search

Dapagliflozin Use in Heart Failure with Reduced Ejection Fraction Accompanied by Type 2 Diabetes Mellitus: A Systematic Review Sinta Dwi Juniar; Mochamad Yusuf Alsagaff; Budi Susetyo Pikir; Pudji Lestari
Cardiovascular and Cardiometabolic Journal Vol. 3 No. 1 (2022): Cardiovascular and Cardiometabolic Journal
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/ccj.v3i1.2022.60-74

Abstract

Abstract: Heart failure patients with reduced ejection fraction (HFrEF) respond well to pharmacological therapy and show a better prognosis. Heart failure patients with reduced ejection fraction and type 2 diabetes who were given SGLT-2 inhibitor therapy showed a strong and consistent reduction in the risk of death and hospitalization. The therapy that has recently begun to be investigated for its benefits for heart failure from the SGLT-2 inhibitor class is Dapagliflozin. The systematic review aims to analyze the effect of Dapagliflozin on the prognosis of HFrEF patients with type 2 diabetes mellitus. Material and Methods: The literature was searched from e-database PubMed, ScienceDirect, and ClinicalTrial.gov. Quality assessment was done using the Critical Appraisal Skills Program (CASP) Randomized Controlled Trial Standard Checklist. Results: A total of 22,167 patients from 4 RCTs eligible studies were included. The analysis results of all of the included studies indicate that Dapagliflozin affected the patient's prognosis. Two studies discuss mortality and hospitalization, and two studies discuss symptoms, functional status, and Quality of Life (QoL). Conclusion: Dapagliflozin can improve the prognosis of HFrEF patients with type 2 DM. The improved prognosis includes reduced mortality, reduced hospitalizations by minimizing disease worsening, reducing symptoms, improving functional status and QoL. Keyword: Cardiovascular disease, Dapagliflozin, Diabetes, Prognosis, SGLT 2 inhibitor
The Association Between Brachial Ankle Pulse Wave Velocity and Left Ventric Mass Index In Patients With Hypertension Budi Susetyo Pikir
Journal of Global Pharma Technology Volume 11 Issue 04.
Publisher : Journal of Global Pharma Technology

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Background: Arterial stiffness has been considered as a modest method in detecting the arterial burden that can trigger left ventricular hypertrophy in the heart. Increased left ventricle hypertrophy in hypertension patients is a predictor which has impact in the increase of morbidity and mortality. Objectives: We aimed to investigate the association between brachial ankle pulse wave velocity (BaPWV) and left ventricle mass index (LVMI) in patients with hypertension. Material and Methods: This study was conducted by collecting secondary data of 40 hypertension patients aged >40 years old, suffered from hypertension >1 year and have encountered brachial ankle pulse wave velocity test and echocardiography test. Results: There was a significant positive correlation between brachial ankle pulse wave velocity and left ventricle mass index in hypertension patients with r = 0.493 dan p = 0.001. Also, there was a significant correlation between BaPWV and Relative Wall Thickness with r = 0.404 and p = 0.01. There was a significant difference of LVMI value in males and females with the result of (117.78+22.70 and 100.15+16.82, p = 0.008). In contrast, there was no significant difference in BaPWV value in males and females (1865.63+322.29 and 1811.08+350.28). It was also obtained a significant correlation between age factor and systolic blood pressure with LVMI and BaPWV (r = 0.493, p = 0.001). Conclusions: There was significant positive correlation between BaPWV and LVMI in hypertension patients. The arterial stiffness was an indicator of increased left ventricle mass index in hypertension patients.Keywords: Brachial ankle pulse wave velocity, Left ventricle mass index, Hypertension, Heart.